Autodesk no longer supports offline activation for 2021 products and earlier. If you have a perpetual license, activate your software by going online only once. After you activate online, you can continue to use 2021 software and earlier offline. This change doesn't apply to previous versions that you already activated offline; you can continue to use them as before.
Activation CFD 2011 Activation
However, for unsupported versions, you can't get a new activation code to reactivate that version for any device. We also do not release software updates or hotfixes for versions that have reached the end of support*.
Blood cell count and factors related to neutrophil activation in HAE attacks compared with symptom-free periods. aWBC, thrombocyte, lymphocyte, and neutrophil-, eosinophil-, and basophil granulocyte count were measured in peripheral blood samples obtained from 14 patients in symptom-free periods and during HAE attacks. The dotted lines indicate normal range. Wilcoxon test (WBC, lymphocyte, neutrophil-, and eosinophil granulocyte) and paired t test (thrombocyte, monocyte, basophil granulocyte) calculations were used. b Levels of neutrophil related factors were measured from plasma samples of 14 patients in symptom-free periods and during HAE attacks. Wilcoxon test (TNFα, IL-8, MPO, LTB4) and paired t test (PRTN3, CCL5, MCP-1, NE, NET) were used
Draftsight 2018 sp3 cannot activate please help I have the problem about activate since Draftsight 2017 so I have to go back using Draftsight 2016 sp2 and hot fix and activation process is working fine every time I enter the information but the latest update build of windows 10 I cannot use Draftsight 2016 sp2 and hot fix anymore so I have to install latest Draftsight 2018 sp3 from -services/draftsight-cad-software/ after I open the program it ask me to migrate from old version and send me to register page and every time I enter information it blink and program is close it-self with no message that said that e-mail was send, I have try all 4 e-mail address that I have without success, I also try all the method mention here including add 3ds.com to trusted website, registry tweak, turn off firewall before activation it give me the same problem every time. my spec is:ASUS S410Ucore i5-8250uram: 8gbSSD: 256GBwindows 10 single language version 1809please help with the activation process
Hello. I have a simillar issue. I install 2018 SP2 (or 1 it does not matter which) and can go through the activation process fine and start the software once. Once I have closed the software and I try to restart it the draftsight start-up windows pops-up and then the software seems to start but direclty shuts down. Once I restart it it will take me to the registration window once again. If i run the activation everything will work but the software will not start. If I clean the registry then it works once again en then bugs again. Any help welcome. BTW= Windows 10 Pro 64
PERFECT! It works. I kept getting the activation message after every restart, even though i activated Draftsight twice. After activation, it would work, but after a computer restart, it would ask again for activation.
Hello Deepak,Thanks for all the good advice. I had the activation problem and after adding Solidworks to the trusted sites list was able to complete the activation form. I did not receive the code to the email address I used (I had used it on a previous registration), but did receive it when I used an alternative email address.
Finely frustration is over after trying for two weeks to reactivate. Once I added to trusted sites per instructions I got the activation email and now I can use the program again.My company recently updated my computer and after re-downloading Draftsight I needed to activate but never got that email. Deepak you are a life saver with this info. Million thanks!
While activation it was possible to enter proxy settings into the wizard, but at starting the program after activation the proxy settings were lost and could not be set (the part where DraftSight tries to verify your activation).
After trying EVERYTHING I found the way:Just disable Windows Firewall to do the activation process.After that, you can use DS normally and set the Firewaal on.(I also allowed DS to jump the Firewall manually)
I am having an issue where every time that I open draftsight it asks me to activate and I have entered a few different email address and I have never gotten an email back to activate it! I had our company IT guy install draftsight for as we also use solidworks, but I still get the activation screen! How do I get rid of the activation window?
Hello, I have this issue as well.Everytime I open Draftsight I am asked to Activate. After filling in the details and hitting the activate button no email is sent. I have tried various email accounts, spam filters are not the issue.My Draftsight install is on a clean install of Window 7 Home Premium x64. I am not the local administrator as this is not an option on a non Professional Windows Licence, I have administrator access however.I have searched everywhere for an answer, other people have posed this question from as far back as early 2011. There are no satisfactory answers. Reinstallation after renaming SwActivation reg key does not work.This is quite a flaw to go unaddressed as it makes Draftsight a chore. Will uninstall the program shortly if not resolved.
Shear-induced platelet activation (SIPAct) is an important mechanism of thrombosis initiation under high blood flow. This mechanism relies on the interaction of platelets with the von Willebrand factor (VWF) capable of unfolding under high shear stress. High shear stress occurs in the arteriovenous fistula (AVF) commonly used for haemodialysis. A novel patient-specific approach for the modelling of SIPAct in the AVF was proposed. This enabled us to estimate the SIPAct level via computational fluid dynamics. The suggested approach was applied for the SIPAct analysis in AVF geometries reconstructed from medical images. The approach facilitates the determination of the SIPAct level dependence on both biomechanical (AVF flow rate) and biochemical factors (VWF multimer size). It was found that the dependence of the SIPAct level on the AVF flow rate can be approximated by a power law. The critical flow rate was a decreasing function of the VWF multimer size. Moreover, the critical AVF flow rate highly depended on patient-specific factors, e.g., the vessel geometry. This indicates that the approach may be adopted to elucidate patient-specific thrombosis risk factors in haemodialysis patients.
Citation: Salikhova TY, Pushin DM, Nesterenko IV, Biryukova LS, Guria GT (2022) Patient specific approach to analysis of shear-induced platelet activation in haemodialysis arteriovenous fistula. PLoS ONE 17(10): e0272342.
In the current study, we have combined computational reconstruction of patient-specific vessel geometry and haemodynamics with a recent mathematical model describing VWF-mediated platelet activation [26]. As a result, a novel patient-specific approach for the modelling of SIPAct has been developed. The capabilities of the approach were demonstrated using personalized data of haemodialysis patients with AVFs. It was found that the dependence of the SIPAct level on the AVF flow rate can be approximated by a power law. The critical AVF flow rate was found to be highly depending on patient-specific factors (e.g., the vessel geometry).
This work is aimed at the analysis of platelet activation initiated by the unfolding of VWF multimers on platelet surfaces [24,26]. VWF unfolding is supposedly initiated under overcritical cumulative shear stress [26]. The subsequent binding of VWF multimers with platelet GPIb receptors triggers outside-in signalling, i.e., platelet priming [47,48]. Platelet priming leads to platelet activation at which conspicuous functional consequences (e.g., P-selection expression) are observed [19]. In this regard, the SIPAct level in the investigated region can be estimated via the calculation of the priming platelet number [49].
The variable of the platelet activation level (PAL) was considered a characteristic of the SIPAct level in the fistulas:(6)where Δt = mΔt0, m denotes the number of cardiac cycles, Δt0 denotes the duration of a cardiac cycle, Ja is the convective flux of the priming platelets, and JΣ is the total convective platelet flux expressed as:(7)(8)where denotes the surface vector of an infinitesimal part of the vein outlet, and P0 was introduced previously (Eq (4)).
The obtained results vary for different patients. Thus, patient-specific factors such as the anatomical structure of the AVF vessel and emerging flow abnormalities might be considered as a source of additional risk of thrombotic complications in haemodialysis patients. Moreover, the approach developed in the current paper allows to quantitatively characterize these individual factors from the point of view of potential platelet activation risk. Further studies on sufficiently large cohorts of patients will be necessary to determine clinical prognostic value of the developed approach [80,81]. Also, a careful correlation analysis including the results of numerical simulations and different other biomarkers (e.g. sP-selectin, GPIIb-IIIa) will be needed to determine the relative impact of SIPAct on the thrombosis risk in haemodialysis patients. Such a broad-scale research might become possible in the nearest future through collaboration with several clinical centers.
It was shown that the shift in the VWF size distribution towards smaller multimers may lead to an increase in the SIPAct level at sufficiently high AVF flow rates (Fig 6A). It may be supposed that the efficacy reduction of antiplatelet therapy in haemodialysis patients could be related to this fact [35,82]. These therapies are based on common drugs that do not sufficiently block shear-induced activation pathway in platelets [20,83,84]. Moreover, a shift in the VWF distribution to smaller multimers has been observed in haemodialysis patients [85]. We suppose that the use of drugs capable of effectively blocking SIPAct should reduce the level of thrombotic complications in haemodialysis patients [86,87]. 2ff7e9595c
Comments